Search details
1.
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor.
Biomed Chromatogr
; 38(2): e5775, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37942577
2.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Article
in English
| MEDLINE | ID: mdl-35641218
3.
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
Invest New Drugs
; 40(4): 782-788, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35435625
4.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.
J Natl Compr Canc Netw
; 20(3): 224-234, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35276673
5.
Genome Sequencing and Apoptotic Markers to Assess Treatment Response of Lacrimal Gland Adenoid Cystic Carcinoma to Intra-Arterial Cytoreductive Chemotherapy.
Ophthalmic Plast Reconstr Surg
; 38(2): e44-e47, 2022.
Article
in English
| MEDLINE | ID: mdl-34798653
6.
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Lancet
; 393(10166): 40-50, 2019 01 05.
Article
in English
| MEDLINE | ID: mdl-30449625
7.
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(7): 873-898, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32634781
8.
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Cancer
; 125(18): 3208-3218, 2019 09 15.
Article
in English
| MEDLINE | ID: mdl-31246283
9.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med
; 375(19): 1856-1867, 2016 11 10.
Article
in English
| MEDLINE | ID: mdl-27718784
10.
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Ann Oncol
; 30(1): 68-75, 2019 01 01.
Article
in English
| MEDLINE | ID: mdl-30407504
11.
Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
J Natl Compr Canc Netw
; 17(9): 1065-1073, 2019 09 01.
Article
in English
| MEDLINE | ID: mdl-31487677
12.
Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
Cancer
; 124(23): 4486-4494, 2018 12 01.
Article
in English
| MEDLINE | ID: mdl-30332498
13.
Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Oncologist
; 23(7): 764-e86, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29540603
14.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Oncologist
; 23(9): 1079-1082, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29866947
15.
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.
J Natl Compr Canc Netw
; 16(5): 479-490, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29752322
16.
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Lancet Oncol
; 18(8): 1104-1115, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28651929
17.
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.
J Natl Compr Canc Netw
; 15(6): 761-770, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28596256
18.
Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas.
Cancer
; 122(9): 1388-97, 2016 05 01.
Article
in English
| MEDLINE | ID: mdl-26969807
19.
Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.
Cancer
; 122(21): 3307-3315, 2016 Nov 15.
Article
in English
| MEDLINE | ID: mdl-27434142
20.
Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.
Cancer
; 122(4): 546-58, 2016 Feb 15.
Article
in English
| MEDLINE | ID: mdl-26588425